The Current Role of Sentinel Lymph Node Biopsy in Breast, Melanoma, and Gastrointestinal Cancers

US Oncological Review, 2008;4(1):11-4

In the two decades that have passed since Morton and colleagues1 introduced their landmark technique for the identification of sentinel lymph node (SN) metastasis in patients with malignant melanoma, sentinel lymph node biopsy (SLNB) has proved to be a remarkable tool in the treatment of solid cancers and has dramatically changed the manner in which regional nodal disease is managed.

The SN concept is that lymphatic flow away from a primary tumor drains through one, or sometimes several, first or SNs as it enters the regional nodal basin. By definition, these nodes receive their drainage directly from the tumor and not from any other nodes. Cancer spread through the lymphatics should first be deposited in the SN and detailed examination of that node should accurately predict the status of the remaining nodal basin. This not only identifies those patients who are most likely to benefit from a completion nodal dissection (CLND), but also results in more accurate pathological staging.

Although SLNB was originally introduced in the management of malignant melanoma, the technique was also rapidly and successfully applied to invasive breast cancer.2 Since then, clinicians have investigated the applicability of SLNB to an ever-increasing number of malignancies, including thyroid cancer, lung cancer, multiple gastrointestinal malignancies, and even head and neck cancer.3–6 The ultimate role of the SN technique is yet to be determined for many of these different malignancies, and refinements to both technique and indication are frequently proposed as worldwide experience increases. This article will focus principally on the current role of SLNB in the management of malignant melanoma, invasive breast cancer, and colon cancer—the three malignancies with the greatest amount of collective data available upon which recommendations can be based. Specific details for the SN technique in treating these cancers and others are sufficiently described elsewhere and will not be emphasized to any great extent here.

References:
  1. Morton DL,Wen DR,Wong JH, et al., Arch Surg, 1992;127:392–9.
  2. Giuliano AE, Kirgan DM, Guenther JM, Morton DL, Ann Surg, 1994;220:391–8.
  3. Bilchik AJ, Giuliano A, Essner R, et al., Cancer J Sci Am, 1998;4:351–8.
  4. Ross GL, Soutar DS, Gordon Macdonald D, et al., Ann Surg Oncol, 2004;11:690–96.
  5. Faries MB, Bleicher RJ, Ye X, et al., Arch Surg, 2004;139:870–76.
  6. Saha S, Wiese D, Badin J, et al., Ann Surg Oncol, 2000;7:120–24
  7. Fortner JG,Woodruff J, Schottenfeld D, Ann Surg, 1977;186:101–3.
  8. Veronesi U, Adamus J, Bandiera DC, et al., Tumori, 1980;66:373–96.
  9. Sim FH, Taylor WF, Ivins JC, et al., Cancer, 1978;41:948–56.
  10. Veronesi U, Adamus J, Bandiera DC, et al., Cancer, 1982;49:2420–30.
  11. Krag DN, Meijer SJ,Weaver DL, et al., Arch Surg, 1995;130:654–8.
  12. Thompson JF, McCarthy WH, Bosch CM, et al., SMelanoma Res, 1995;5:255–60.
  13. Albertini JJ, Cruse CW, Rapaport D, et al., Ann Surg, 1996;223: 217–24.
  14. Leong SP, Steinmetz I, Habib FA, et al., Arch Surg, 1997;132:666–72.
  15. Essner R, Bostick PJ, Glass EC, et al., Surgery, 2000;127:26–31.
  16. Balch CM, Soong SJ, Bartolucci AA, et al., Ann Surg, 1996;224: 255–66.
  17. Balch CM, Soong SJ, Ross MI, et al., Ann Surg Oncol, 2000;7:87–97.
  18. Morton DL, Thompson JF, Cochran AJ, et al., N Engl J Med, 2006;335:1307–17.
  19. Kalady MF, White RR, Johnson JL, et al., Ann Surg, 2003;238:528–35.
  20. Wong SL, Brady MS, Busam KJ, Coit DG, Ann Surg Oncol, 2006;13:302–9.
  21. Ranieri JM,Wagner JD,Wenck S, et al., Ann Surg Oncol, 2006;13:927–32.
  22. Hershko DD, Robb BW, Lowy AM, et al., J Surg Oncol, 2006;93:279–85.
  23. Wright BE, Scheri RP, Xing Y, et al., Arch Surg, 2008;143:182–9.
  24. Gershenwald JE, Mansfield PF, Lee JE, Ross MI, Ann Surg Oncol, 2000;7:160–65.
  25. National Cancer Care Network (NCCN) Breast Cancer. 2007/2008 National Comprehensive Cancer Network, 2008. Available at: www.nccn.org
  26. Siegel BM, Mayzel KA, Love SM, Arch Surg, 1990;125:1144–7.
  27. Giuliano AE, Jones RC, Brennan M, et al., J Clin Oncol, 1997;15:2345–50.
  28. Krag D,Weaver D, Ashikaga T, et al., N Engl J Med, 1998;339:941–6.
  29. McMasters KM, Tuttle TM, Carlson DJ, et al., J Clin Oncol, 2000;18:2560–66.
  30. Hsueh EC, Hansen N, Giuliano AE, et al., Cancer J Clin, 2000;50:279–91.
  31. Cascinelli N, Greco M, Bufalino R, et al., Eur J Clin Oncol, 1987;23:795–9.
  32. Chen SL, Hoehne FM, Giuliano AE, Ann Surg Oncol, 2007;14:3378–84.
  33. Cox CE, Kiluk JV, Riker AI, et al., J Am Coll Surg, 2008;206: 261–8.
  34. Sabel MS, Schott AF, Kleer GC, et al., Am J Surg, 2003;186: 102–5.
  35. Yen TW, Hunt KK, Ross MI, et al., J Am Coll Surg, 2005;200:515–26.
  36. Cohen AM, Kelsen D, Saltz L, et al., Curr Prob Cancer, 1998;22:5–65.
  37. Tsioulias GJ,Wood TF, Morton DL, et al., Arch Surg, 2000;135:926–32.
  38. Bertagnolli M, Miedema B, Redston M, et al., Ann Surg, 2004;240:624–8.
  39. Bilchik AJ, DiNome M, Saha S, et al., Arch Surg, 2006;141:527–33.
  40. Bembenek AE, Rosenburg R,Wagler E, et al., Ann Surg, 2007;245:858–63.
  41. Stojadinovic A, Nissan A, Protic M, et al., Ann Surg, 2007;245:846–57.
  42. Lim SJ, Feig BW,Wang H, et al., Ann Surg Oncol, 2008;15: 46–51.
  43. Bilchik AJ, Hoon DS, Saha S, et al., Ann Surg, 2007;246:568–75.
  44. Hayashi H, Ochiai T, Mori M, et al., J Am Coll Surg, 2003;196: 68–74.
Customize This